Amrie Grammer is co-founder of AMPEL, a company that combines genetics and big data to discover new medical treatments. (Credit Amrie Grammer)
Getting approval for new drugs takes years and costs companies millions of dollars. What’s more, clinical trials sometimes fail, leaving firms with nothing to show.
Now, however, a Virginia company is taking a different approach – looking at drugs that already have FDA approval to see what other conditions they might treat.
Sandy Hausman explains.
